AI assistant
GlaxoSmithKline PLC Remuneration Information 2021
5262_def-14a_2021-03-02_36437ca6-2c17-4691-8177-155b31907b3f.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 9116Q
GlaxoSmithKline PLC
02 March 2021
GlaxoSmithKline plc (the 'Company')
Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American Depository Shares
This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares ('ADSs') made in 2018 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares and ADSs to meet tax liabilities. In accordance with the shareholder approved 2017 Remuneration Policy and the DABP rules, the awards were comprised of a mandatory bonus deferral only. The three-year restricted period for the Deferred Bonus Awards commenced on 1 March 2018 and ended on 1 March 2021. Dividends accrued on the Awards during the restricted period.
The awards were granted in 2018 as restricted awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.
The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on 1 March 2021 were £12.0060 and $33.73.
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms E Walmsley | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 68,716 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms E Walmsley | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £12.1070 | 32,346 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr R Connor | |||
| b) | Position/status | President, Global Vaccines | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 14,551 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr R Connor | |||
| b) | Position/status | President, Global Vaccines | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £12.1113 | 6,857 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr N Hirons | |||
| b) | Position/status | SVP, Global Ethics and Compliance | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 7,630 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr N Hirons | |||
| b) | Position/status | SVP, Global Ethics and Compliance | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £12.1132 | 3,599 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr B McNamara | |||
| b) | Position/status | CEO, GSK Consumer Healthcare | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
|||
| b) | Nature of the transaction | The vesting of an award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 7,346 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr B McNamara | |||
| b) | Position/status | CEO, GSK Consumer Healthcare | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
|||
| b) | Nature of the transaction | The sale of ADSs' to meet tax liabilities on the vesting of an award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $33.7970 | 3,756 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr L Miels | |||
| b) | Position/status | President, Global Pharmaceuticals | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 13,820 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr L Miels | |||
| b) | Position/status | President, Global Pharmaceuticals | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £12.0992 | 6,501 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr D Redfern | |||
| b) | Position/status | Chief Strategy Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 14,126 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr D Redfern | |||
| b) | Position/status | Chief Strategy Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £12.1093 | 6,656 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms K Terrell | |||
| b) | Position/status | Chief Digital & Technology Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
|||
| b) | Nature of the transaction | The vesting of an award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 2,480 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms K Terrell | |||
| b) | Position/status | Chief Digital & Technology Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
|||
| b) | Nature of the transaction | The sale of ADSs' to meet tax liabilities on the vesting of an award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $33.7970 | 976 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr P Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 9,555 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr P Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GlaxoSmithKline plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan. | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £12.1030 | 4,507 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2021-03-01 | |||
| f) | Place of the transaction | N/A |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHELLFBFXLZBBQ